

# Breast Cancer Control in Rural Settings

8<sup>th</sup> Annual Vermont Center on Behavior and Health Conference  
October 8, 2020

Brian Sprague, PhD  
Associate Professor  
Departments of Surgery, Radiology, and Biochemistry  
University of Vermont

THE  
University of Vermont  
CANCER CENTER





Vermont Center on  
Behavior & Health  
The University of Vermont

# Disclosures

- I have no disclosures to report.


# Urban-Rural Disparities in Cancer

All sites




□ Nonmetropolitan rural    ■ Nonmetropolitan urban    ■ Metropolitan with <1 million population    ■ Metropolitan with ≥1 million population

# Urban-Rural Disparities in Cancer




# Breast Cancer Survival




# Studying Breast Cancer in Vermont

- 61% of Vermont's population lives in rural areas as defined by US Census
  - 2<sup>nd</sup> in US only to Maine
- Adult female population ~240,000
  - About 500 breast cancers diagnosed per year



# Breast Cancer Survival in Vermont


- Among women diagnosed with breast cancer in Vermont, those living in isolated rural areas of Vermont had 44% increased risk of breast cancer death compared to women living in urban areas.



KC Bolton, unpublished findings.


# The Vermont Breast Cancer Surveillance System

- Statewide medical records registry for all women undergoing breast imaging at Radiology facilities in Vermont
  - Established in 1993
  - Funded by research grants from NCI, PCORI
- Data sources
  - 15 breast imaging facilities
  - 10 pathology facilities
    - Abstraction from path reports
  - Linkage to Vermont Cancer Registry and state vital records
  - Algorithms to ensure patient matching across data streams






# Data Collection



**Ancillary Studies**  
 Radiologic images  
 Tissue specimens  
 Patient surveys  
 Provider surveys

# The Breast Cancer Surveillance Consortium (BCSC)


*The nation's largest longitudinal collection of mammography data from breast cancer screening in community practice (13 million mammograms, 3 million women)*



# Investigating Breast Cancer Control in Rural Populations

## The Cancer Control Continuum





### Process Measures

Risk assessment performed	Risk-based modality, imaging performance, additional imaging, timeliness, screening rates	Utilization, intensity, timeliness	Timeliness, adherence, care coordination
---------------------------	---	------------------------------------	--

### Outcome Measures

Risk score (Lifetime & 5 year)	Assessment & recommendation, sensitivity, specificity, PPV, cancer detection rate, recall rate	Biopsy yield, stage, EOD, tumor characteristics, PPV	Quality of life, follow-up for cancer & death
--------------------------------	--	--	---

Onega et al., 2014  
Cancer 120:2955-2964


# Investigating Breast Cancer Control in Rural Populations

- Prevention
- Detection
  - Access to screening & diagnostic imaging
  - Quality of imaging interpretation
- Diagnosis
  - Access to biopsy services
  - Timeliness of diagnosis
- Treatment
  - Access and adherence to treatment
- Survivorship

# Screening Utilization in Vermont

- Persistent decline in Vermont women adhering to screening recommendations

**Percent of Vermont Women Screened in the Past 2 Years**




# Screening

- National studies report that women living in rural areas have slightly lower utilization of breast cancer than women in urban areas
- Women living in counties with few or no mammography machines have lower screening rates
  - Need mobile vans, subsidies for purchase of machines, increased reimbursement, incentives for providers to practice in underserved areas

# Detection: Mammography Interpretive Performance

- Mammography screening performance varies across providers in Vermont
  - 15 Vermont facilities
    - sensitivity 75-93%
    - specificity 79-95%
  - 51 Vermont radiologists
    - sensitivity 71-98%
    - specificity 73-97%






# Detection: Mammography Interpretive Performance

- BCSC studies have shown that mammographic accuracy is lower among:
  - General radiologists vs. breast specialists
  - Low volume vs. high volume readers
  - Radiologists with less years of experience
- Many rural facilities are served by general radiologists who read low volume of mammograms
  - 70% of rural physicians interpret <1000 mammograms per year (vs. 55% urban)
- 23% of rural facilities performed <1000 mammograms per year


# Mammography Interpretive Performance

- BCSC analyses of screening mammography performance at 151 facilities
  - No difference in sensitivity or specificity at rural vs. urban facilities after adjusting for patient-level factors (age, time since last mammogram, etc.)
  - Timeliness of follow-up with additional imaging after abnormal screen is comparable at rural vs. urban facilities.



# Mammography Interpretive Performance

- BCSC analyses of diagnostic mammography
  - Comparable sensitivity at rural vs. urban facilities
  - Poorer specificity at rural facilities, corresponding to a **55%** higher false positive rate
  - Unnecessary additional imaging and biopsies




# Investigating Breast Cancer Control in Rural Populations

- Prevention
- Detection
  - Access to screening & diagnostic imaging
  - Quality of imaging interpretation
- Diagnosis
  - Access to biopsy services
  - Timeliness of diagnosis
- Treatment
  - Access and adherence to treatment
- Survivorship

# Diagnosis of Breast Cancer


- Use of needle biopsy rather than surgical biopsy is a Quality of Care measure from the Commission on Cancer
  - Rate of needle biopsy should meet or exceed 90%
- Surgical biopsy
  - Increased patient discomfort, increased risk for wound complications
  - Prolonged recovery compared to MIBB
  - Disruption of tumor margins
- Needle biopsy
  - Less unlikely to have unnecessary surgery
  - More likely to have negative margins at time of first surgery
  - Allows for neo-adjuvant therapy



# Breast Biopsy in Vermont

- Open surgical excision was nearly one-third of the biopsies performed in Vermont in the year 1999
- Large disparity in biopsy type for rural vs. urban residents has essentially been erased.
- By 2013, the needle biopsy rate exceeded 90% for rural women in Vermont


Percent of Biopsies that were Needle vs. Surgical



James et al. 2012, *J Am Coll Surg*  
Murphy et al., in preparation

## Breast Biopsy - results

- 3 of 13 hospitals in Vermont still have needle biopsy rate <90%
  - Some facilities can only perform ultrasound-guided needle biopsy.
  - Do not have equipment for stereotactic (mammography-guided) needle biopsy
    - If lesion is only seen on mammography (not ultrasound) then patient must choose whether to travel for stereotactic biopsy



Murphy et al., in preparation

# Diagnosis of Breast Cancer

- BCSC analysis of timeliness of diagnosis after positive diagnostic mammogram
  - Follow-up for biopsy/surgical consultation is slower in rural (38% in 15 days) vs. urban facilities (57% in 15 days).
    - And 5% less likely to follow through with biopsy.

Goldman 2013 *Medical Care* 51:307-314



# Investigating Breast Cancer Control in Rural Populations


- Prevention
- Detection
  - Access to screening & diagnostic imaging
  - Quality of imaging interpretation
- Diagnosis
  - Access to biopsy services
  - Timeliness of diagnosis
- Treatment
  - Access and adherence to treatment
- Survivorship

## Access to Cancer Care

- Rural women in breast cancer treatment randomized trials have similar outcomes to urban women
  - When treatments are carefully managed/arranged, rural patients have comparable survival
- There are many fewer specialist physicians in rural vs. urban areas
  - Less than 50% of cancer patients living in small and isolated rural areas have a medical or radiation oncologist within 30 miles (compared to >98% for urban patients)

## Access to Cancer Care

- Median drive times for small town and isolated rural areas:
  - 180 minute drive to the nearest NCI-designated cancer center
  - 105 minutes to academic medical center
  - 59 minutes to any specialized cancer care setting
- Travel time to a facility is associated with treatment choice
  - Choosing “low frequency” service (mastectomy rather than lumpectomy + radiation)



## Time to Chemotherapy

- In Vermont, drive time to the treatment facility is associated with delayed initiation of chemotherapy
  - 702 women diagnosed with stage I-III breast cancer in Vermont
  - Determined time between date of diagnosis and initiation of chemotherapy
  - Multivariable adjustment for stage, surgery type, age, hospital

Drive-Time Group	Mean (weeks)	25 <sup>th</sup> Percentile (weeks) (95% CI)	50 <sup>th</sup> Percentile (weeks) (95% CI)	75 <sup>th</sup> Percentile (weeks) (95% CI)
<15 minutes	9.6	7.6 (7.0,8.0)	9.2 (8.7,9.8)	11.5 (11.0,12.1)
15-29 minutes	9.4	7.0 (5.8,7.1)	9.0 (8.1,9.7)	12.0 (10.4,13.0)
30-44 minutes	9.6	6.5 (6.0,7.4)	9.6 (8.1,10.7)	12.1 (11.0,13.4)
45-59 minutes	10.0	6.4 (5.4,7.8)	9.4 (8.4,10.5)	13.0 (11.8,14.5)
60+ minutes	11.7	8.2 (8.0,9.2)	11.0 (10.1,11.8)	14.2 (13.5,15.2)

# Summary

- Compared to women in urban areas, women in rural areas have:
  - Lower incidence of breast cancer
  - Comparable screening utilization, high quality screening mammography performance
  - Worse performance of diagnostic mammography (higher false positive rate)
  - Delays in biopsy and lower access to needle biopsy
  - Impaired access to treatments
  - Worse survival after diagnosis
- Themes
  - Access to high quality specialized care is a significant challenge
    - Especially care requiring multiple visits

## Interventions

- Patient navigation programs
- Transportation assistance programs
- Guest housing near oncology practices
- Expanded services (mammography, chemotherapy, etc.) at local facilities
- Mobile services (mammography, chemotherapy)
- Remote interpretation of diagnostic mammography
- Need subsidies, reimbursement, incentives, etc., for all of the above

# Acknowledgements

*All the participating women, healthcare providers, and facilities!*

## Collaborators

<u>UVM</u>	<u>BCSC</u>	<u>PROSPR</u>	<u>Vermont Dept of Health</u>	<u>VBCSS Staff</u>
Donald Weaver	Diana Miglioretti	Emily Conant	Alison Johnson	Mark Bowman
Sally Herschorn	Karla Kerlikowske	Bill Barlow	Jennifer Kachajian	Michael Butler
Pamela Vacek	Anna Tosteson	Jennifer Haas	Leanne Shulman	Meghan Farrington
Berta Geller	Diana Buist	Mitch Schnall		Cindy Groseclose
Kenyon Bolton	Louise Henderson	Katrina Armstrong		Kathleen Howe
Serena Murphy	Tracy Onega	Anne Marie McCarthy		Denis Nunez
Caitlin Beaudet	Garth Rauscher	Despina Kontos		Dawn Pelkey
				Dusty Quick
				Tiffany Sharp

## Funding

National Cancer Institute (R01 CA248068, U54 CA163303, P01 CA154292), National Institute of General Medical Sciences (P20 GM103644), Patient-Centered Outcomes Research Institute (PCS-1504-30370)